MoonLake Immunotherapeutics Accounts Payable

MoonLake Immunotherapeutics (MLTX) currently reports a accounts payable of $17M as of June 2026. That compares with $15M in the prior-year period — up 14.4% year over year. Use the charts on this page to explore MoonLake Immunotherapeutics's accounts payable history and peer comparisons.

MoonLake Immunotherapeutics's accounts payable increased from $15M to $17M — a 14.4% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

MoonLake Immunotherapeutics reported $17M in accounts payable as of June 2026. That compares with $15M in the prior-year period — up 14.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $17M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for MoonLake Immunotherapeutics, and consider following MLTX for alerts when major investors trade the stock.